Geroprotective Agents and Topical Peptides Tested for Biological Age Reversal Using Epigenetic Clocks

Aging is a complex process affecting both systemic health and skin integrity, driven by intrinsic genetic programs and extrinsic stressors like UV and inflammation. Current anti-aging strategies often target symptoms rather than underlying mechanisms. Epigenetic clocks, based on DNA methylation patterns, have emerged as precise biomarkers for biological age, offering a quantitative measure beyond chronological age. These clocks can track both intrinsic aging and environmental stress, making them ideal tools to assess interventions. This study aims to determine if specific geroprotective agents and anti-aging peptides can modulate these epigenetic markers, potentially reversing or slowing the aging process.

This human study investigates the impact of geroprotective agents and topical treatments on biological age. Adult participants receive systemic geroprotective agents orally or via injection. Concurrently, a skin serum containing small anti-aging peptides is applied topically to specific skin areas, with untreated areas serving as within-subject controls. Blood and skin samples are collected at predetermined intervals (before, during, and after treatment) to measure biological age using START/REST Aging Clocks and other markers of cellular aging. The primary endpoint is to assess whether these treatments lead to a reduction in measured biological age in both skin and blood, while also monitoring safety and tolerability.